Literature DB >> 29907605

Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy.

Pierre Lozeron1, Louise-Laure Mariani2, Pauline Dodet2, Guillemette Beaudonnet2, Marie Théaudin2, Clovis Adam2, Bertrand Arnulf2, David Adams2.   

Abstract

OBJECTIVE: To clearly define transthyretin familial amyloid polyneuropathies (TTR-FAPs) fulfilling definite clinical and electrophysiologic European Federation of Neurological Societies/Peripheral Nerve Society criteria for chronic inflammatory demyelinating polyneuropathy (CIDP).
METHODS: From a cohort of 194 patients with FAP, 13 of 84 patients (15%) of French ancestry had late-onset demyelinating TTR-FAP. We compared clinical presentation and electrophysiology to a cohort with CIDP and POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome. We assessed nerve histology and the correlation between motor/sensory amplitudes/velocities. Predictors of demyelinating TTR-FAP were identified from clinical and electrophysiologic data.
RESULTS: Pain, dysautonomia, small fiber sensory loss above the wrists, upper limb weakness, and absence of ataxia were predictors of demyelinating TTR-FAP (p < 0.01). The most frequent demyelinating features were prolonged distal motor latency of the median nerve and reduced sensory conduction velocity of the median and ulnar nerves. Motor axonal loss was severe and frequent in the median, ulnar, and tibial nerves (p < 0.05) in demyelinating FAP. Ulnar nerve motor amplitude <5.4 mV and sural nerve amplitude <3.95 μV were distinguishing characteristics of demyelinating TTR-FAP. Nerve biopsy showed severe axonal loss and occasional segmental demyelination-remyelination.
CONCLUSION: Misleading features of TTR-FAP fulfilling criteria for CIDP are not uncommon in sporadic late-onset TTR-FAP, which highlights the limits of European Federation of Neurological Societies/Peripheral Nerve Society criteria. Specific clinical aspects and marked electrophysiologic axonal loss are red flag symptoms that should alert to this diagnosis and prompt TTR gene sequencing.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 29907605     DOI: 10.1212/WNL.0000000000005777

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

2.  Patterns of myelinated nerve fibers loss in transthyretin amyloid polyneuropathy and mimics.

Authors:  Kang Du; Xujun Chu; Yuwei Tang; Xutong Zhao; Meng Yu; Yiming Zheng; Jianwen Deng; He Lv; Wei Zhang; Zhaoxia Wang; Yun Yuan; Lingchao Meng
Journal:  Ann Clin Transl Neurol       Date:  2022-06-04       Impact factor: 5.430

3.  High-resolution ultrasound of peripheral nerves in late-onset hereditary transthyretin amyloidosis with polyneuropathy: similarities and differences with CIDP.

Authors:  Luca Leonardi; Giuseppe Di Pietro; Antonella Di Pasquale; Fiammetta Vanoli; Laura Fionda; Matteo Garibaldi; Eleonora Galosi; Girolamo Alfieri; Antonio Lauletta; Stefania Morino; Marco Salvetti; Andrea Truini; Giovanni Antonini
Journal:  Neurol Sci       Date:  2021-11-21       Impact factor: 3.830

Review 4.  Advances in the treatment of hereditary transthyretin amyloidosis: A review.

Authors:  Morie A Gertz; Michelle L Mauermann; Martha Grogan; Teresa Coelho
Journal:  Brain Behav       Date:  2019-08-01       Impact factor: 2.708

5.  Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren's Syndrome.

Authors:  Tabea Seeliger; Nils K Prenzler; Stefan Gingele; Benjamin Seeliger; Sonja Körner; Thea Thiele; Lena Bönig; Kurt-Wolfram Sühs; Torsten Witte; Martin Stangel; Thomas Skripuletz
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

Review 6.  Amyloid Proteins and Peripheral Neuropathy.

Authors:  Mohammed M H Asiri; Sjoukje Engelsman; Niels Eijkelkamp; Jo W M Höppener
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

7.  Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.

Authors:  Xiaochen Lin; Aaron Yarlas; Montserrat Vera-Llonch; Nishtha Baranwal; Josh Biber; Duncan Brown; Braden Vogt; Chafic Karam
Journal:  BMC Neurol       Date:  2021-02-12       Impact factor: 2.474

Review 8.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini
Journal:  J Neurol       Date:  2020-01-06       Impact factor: 4.849

Review 9.  Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.

Authors:  Marco Luigetti; Angela Romano; Andrea Di Paolantonio; Giulia Bisogni; Mario Sabatelli
Journal:  Ther Clin Risk Manag       Date:  2020-02-21       Impact factor: 2.423

10.  Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.

Authors:  Morie Gertz; David Adams; Yukio Ando; João Melo Beirão; Sabahat Bokhari; Teresa Coelho; Raymond L Comenzo; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Julian D Gillmore; Martha Grogan; Philip N Hawkins; Isabelle Lousada; Arnt V Kristen; Frederick L Ruberg; Ole B Suhr; Mathew S Maurer; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Ronald Witteles; Giampaolo Merlini
Journal:  BMC Fam Pract       Date:  2020-09-23       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.